Literature DB >> 9140429

Hormone-metabolic status in moderately smoking breast cancer patients.

L M Berstein1, E V Tsyrlina, V F Semiglazov, I G Kovalenko, V B Gamayunova, T P Evtushenko, O A Ivanova.   

Abstract

One hundred and eighteen primary breast cancer (BC) patients, 35 of whom were smokers, in clinical stages I-II of the disease were examined. In order to investigate whether smoking changes endocrine function in BC patients, some indices of the hormone-metabolic status of smoking and non-smoking patients of reproductive and menopausal age were compared. It was found that in smokers with BC there was a decline in body weight and body fat content, a lack of lean body mass accumulation along with body mass increase, a tendency to hypotriglyceridemia and hypoinsulinemia, accelerated development of the upper type of body fat distribution with ageing, intensified gonadotropin secretion, shifts in steroidogenesis and SHBG level and elevated catecholamine execretion. It is suggested that a possible relation between hormone-mediated effects inherent to smoking and the mechanisms promoting genotoxic type of hormonal carcinogenesis and the factors of breast cancer prognosis cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9140429     DOI: 10.3109/02841869709109221

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  2 in total

1.  Preoperative blood-routine markers and prognosis of esophageal squamous cell carcinoma: The Fujian prospective investigation of cancer (FIESTA) study.

Authors:  Dan Hu; Xiandong Lin; Yan Chen; Qing Chang; Gang Chen; Chao Li; Hejun Zhang; Zhaolei Cui; Binying Liang; Wenhui Jiang; Kaida Ji; Jun Huang; Feng Peng; Xiongwei Zheng; Wenquan Niu
Journal:  Oncotarget       Date:  2017-04-04

2.  The red distribution width and the platelet distribution width as prognostic predictors in gastric cancer.

Authors:  Shiqing Cheng; Fuyan Han; Yong Wang; Yanqiu Xu; Teng Qu; Ying Ju; Zhiming Lu
Journal:  BMC Gastroenterol       Date:  2017-12-20       Impact factor: 3.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.